Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simplivir
- Development stage
- Discontinued
- Lead developer
- CytoGenix
- Modality
- Gene Addition/Replacement → Gene Therapies, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies
- Administration
- Oral, Intravenous, Topical, Ophthalmic
01
Overview
Simplivir is an experimental DNA-based antiviral therapeutic developed by CytoGenix for the treatment of herpes simplex virus (HSV) infections. The product was designed using CytoGenix's proprietary synthetic DNA (synDNA) manufacturing technology, which aimed to produce high-purity, linear DNA sequences more efficiently than traditional plasmid-based methods. Simplivir was intended to function as either a DNA vaccine or a gene-silencing therapy to inhibit HSV replication or stimulate a targeted immune response. In 2007, CytoGenix expanded its manufacturing capabilities to support the production of Simplivir and its influenza vaccine candidates. However, the development of Simplivir appears to have been discontinued following the company's subsequent financial and legal challenges in the late 2000s.
- Brand names
- Simplivir
02
Targets
HSV-1 (Herpes simplex virus type 1)
Beyond the preview
Go deeper on Simplivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simplivir.